JCO Global Oncology最新文献

{"title":"Erratum: Factors Affecting Breast Cancer Screening in Ukraine.","authors":"","doi":"10.1200/GO-24-00447","DOIUrl":"https://doi.org/10.1200/GO-24-00447","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400447"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic Landscape in Prostate Cancer in a Latin American Population.","authors":"Martín Angel, Berenice Freile, Andres Rodriguez, Federico Cayol, Ray Manneh Kopp, Patricia Rioja, Tomas Soule, Federico Losco, Laura Bernal Vaca, Jose Mauricio Penaloza, Maycos Leandro Zapata Muñoz, Silvia Patricia Neciosup, Roger Rodrigo Sanchez, Carolina Passarella, Elvio Guerreño, Diego Farelluk, Ernesto Maturana Leiva, Martin Zarba, Maria Teresa Bourlon, Mauricio Mora Pineda, Juan Pablo Sade","doi":"10.1200/GO.24.00072","DOIUrl":"10.1200/GO.24.00072","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to describe genomic characteristics of patients with metastatic prostate cancer (mPC).</p><p><strong>Patients and methods: </strong>This study is a retrospective, multicenter cohort study of patients with mPC and reports on genomic testing. Patients were included from 12 academic centers in five countries.</p><p><strong>Results: </strong>A total of 349 patients with PC were included in this study. Most patients (209, 59.9%) were de novo metastatic. Genomic analysis was performed in 233 (66.6%) patients in the metastatic castration-resistant prostate cancer (mCRPC) setting, and only 115 (32.8%) patients had a tumor evaluation in the metastatic hormone sensitive prostate cancer scenario. The evaluation of somatic and/or germline mutations was performed through multigene panel analyses in 290 (83.09%) patients, and next-generation sequencing of <i>BRCA1</i> and <i>BRCA2</i> genes was performed in 59 (16.91%) patients. Analyzing the mCRPC subgroup, with a median follow-up of 15.6 months (IQR, 14-19.06), the median progression-free survival (PFS) was not reached (NR) and the PFS at 16 months was 58.7% (95% CI, 50.8 to 67.8). When comparing patients with <i>BRCA</i> mutations with those who are not <i>BRCA</i>-mutated in the mCRPC scenario, the median PFS was NR (95% CI, 14 to NR) and 26.3 months (95% CI, 16.7 to 36.5; <i>P</i> = .2), respectively. Two of six patients with <i>BRCA</i> mutations were treated with targeted therapies (poly-ADP-ribose polymerase inhibitors).</p><p><strong>Conclusion: </strong>Our study, to the best of our knowledge, represents one of the larger data sets for somatic testing in patients with PC in Latin America (LATAM). It adds valuable information to the growing body of knowledge about the genomic landscape of advanced PC in real-world daily practice scenarios in LATAM countries, which are not always well-represented in large-scale randomized clinical trials.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400072"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Dietary Patterns and Risk of Breast Cancer in Africa: A Systematic Review.","authors":"","doi":"10.1200/GO-24-00405","DOIUrl":"https://doi.org/10.1200/GO-24-00405","url":null,"abstract":"","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400405"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142143068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to S. Najem et al.","authors":"Khalid El Bairi, Dario Trapani","doi":"10.1200/GO-24-00331","DOIUrl":"https://doi.org/10.1200/GO-24-00331","url":null,"abstract":"<p><p>The emergence of predatory oncology journals represents a significant threat to research integrity. Distance-education approaches to inform oncologists about this risk is promising and effective, particularly for LMICs, as it offers flexibility and affordability.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400331"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521.","authors":"Bin-Chi Liao, Nai-Jung Chiang, Gee-Chen Chang, Wu-Chou Su, Yung-Hung Luo, Inn-Wen Chong, Tsung-Ying Yang, Chun-Liang Lai, Te-Chun Hsia, Ching-Liang Ho, Kang-Yun Lee, Chin-Fu Hsiao, Fan-Chen Ku, Wei-Tse Fang, James Chih-Hsin Yang","doi":"10.1200/GO.24.00125","DOIUrl":"10.1200/GO.24.00125","url":null,"abstract":"<p><strong>Purpose: </strong>Tissue-based next-generation sequencing (NGS) analysis is highly recommended for patients with advanced/metastatic non-small cell lung cancer (NSCLC). We investigated a specific patient population with NSCLC that required tissue-based NGS analysis.</p><p><strong>Materials and methods: </strong>We enrolled 500 patients with advanced/metastatic (1) epidermal growth factor receptor (<i>EGFR</i>) mutations or anaplastic large-cell lymphoma kinase (<i>ALK</i>) rearrangement-positive NSCLC who had failed at minimum one line of tyrosine kinase inhibitor (TKI) therapy, (2) <i>EGFR-/ALK</i>-negative nonsquamous, and (3) non- or light-smoker patients with squamous NSCLC who were treatment-naïve or had failed at maximum two lines of systemic treatment. These patients were divided into five cohorts. Comprehensive tissue-based NGS testing (ACTOnco+) was conducted.</p><p><strong>Results: </strong>Cohort 1: EGFR TKI-pretreated <i>EGFR</i>-mutated population (50.0%, n = 250), cohort 2: ALK inhibitor-pretreated <i>ALK</i>-positive population (1.6%, n = 8), cohort 3: treatment-naïve <i>EGFR-/ALK</i>-negative population (28.2%, n = 141), cohort 4: pretreated <i>EGFR-/ALK</i>-negative population (16.8%, n = 84), and cohort 5: squamous cell carcinoma (3.4%, n = 17). In cohort 1, 11.2% (28/250) of the patients had <i>MET</i> amplification, 32.4% (81/250) had been treated with osimertinib, and <i>EGFR</i> C797S was detected in 6.2% (5/81) of these patients. In cohort 2, resistance ALK mutation was detected in 37.5% (3/8) of the patients. In cohorts 3 and 4, targetable genetic alterations, including <i>EGFR</i> mutation (13.3%), <i>ERBB2</i> mutation (9.3%), <i>MET</i> exon 14 skipping (5.3%), <i>KRAS</i> G12C mutation (4.4%), <i>ROS1</i> fusion (2.7%), <i>RET</i> fusion (1.8%), and <i>BRAF</i> V600E mutation (1.3%), were detected. In cohort 5, <i>MET</i> exon 14 skipping was detected in 29.4% (5/17) of the patients.</p><p><strong>Conclusion: </strong>This multicenter registration study investigated tissue-based NGS for a specific patient population with NSCLC in Taiwan.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400125"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Analysis of Metastatic Prostate Cancer: Real-World Data From the Middle East.","authors":"Ramiz Abu-Hijlih, Samer Salah, Haneen Abaza, Ayat Taqash, Hadeel Abdelkhaleq, Akram Al-Ibraheem, Amal Al-Omari","doi":"10.1200/GO.24.00042","DOIUrl":"https://doi.org/10.1200/GO.24.00042","url":null,"abstract":"<p><strong>Purpose: </strong>Metastatic prostate cancer (Pca) is a complex disease with diverse clinical characteristics and outcomes across the geographical distribution. Herein, we present a series of patients from the Middle East, aiming at identifying disease outcomes and prognostic factors specific to this regional context.</p><p><strong>Methods and materials: </strong>This is a retrospective study of patients with metastatic Pca, diagnosed at King Hussein Cancer Center, Jordan, between 2006 and 2018. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Factors that significantly affected overall survival (OS) in the univariable analysis were examined in a multivariable Cox regression analysis.</p><p><strong>Results: </strong>A total of 188 patients with metastatic Pca were included in this analysis, of whom 168 (89%) had de novo metastatic disease. The median age at diagnosis was 68 years, 144 (77%) had bone metastasis, 32 (17%) had visceral metastasis, and 126 (67%) had high-volume disease. At a median follow-up of 67 months, the median OS was 44.3 months. The following factors predicted inferior OS in univariable analysis: smoking, normal BMI, high-volume disease, high alkaline phosphatase (ALP), previous local therapy for prostate, and orchiectomy versus medical androgen deprivation therapy (ADT). On multivariable analysis, high-volume disease (hazard ratio [HR], 1.92 [95% CI, 1.17 to 3.13]; <i>P =</i> .0094), high ALP (HR, 2.136 [95% CI, 1.38 to 3.31]; <i>P <</i> .001), and orchiectomy (HR, 2.40 [95% CI, 1.51 to 3.82]; <i>P <</i> .001) emerged as independent factors for inferior OS.</p><p><strong>Conclusion: </strong>Metastatic Pca outcomes in our population closely align with the global benchmark. High volume status, elevated ALP, and performance of surgical as opposed to medical ADT emerge as prognostic indicators of poor survival.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400042"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the Early Phase of the COVID-19 Pandemic on the Quality of Care for Colorectal and Anal Cancers at Comprehensive Cancer Centers on Two Continents.","authors":"Erick F Saldanha, Melanie Powis, Divya Sharma, Osvaldo Espin-Garcia, Saidah Hack, Felicia Cavalher, Maria Rita Costa, Maria Simoes, Huaqi Li, Abed Baiad, Kevin Chen, Zuhul Mohmand, Peter Nakhla, Samuel Aguiar, Rachel Riechelmann, Monika K Krzyzanowska","doi":"10.1200/GO.24.00037","DOIUrl":"10.1200/GO.24.00037","url":null,"abstract":"<p><strong>Purpose: </strong>The early phase of the COVID-19 pandemic affected cancer care globally. Evaluating the impact of the pandemic on the quality of cancer care delivery is crucial for understanding how changes in care delivery may influence outcomes. Our study compared care delivered during the early phase of the pandemic with the same period in the previous year at two institutions across continents (Princess Margaret Cancer Center [PM] in Canada and A.C. Camargo Cancer Center [AC] in Brazil).</p><p><strong>Methods: </strong>Patients newly diagnosed with colorectal or anal cancer between February and December 2019 and the same period in 2020 were analyzed. Sociodemographic and clinical characteristics and performance of individual indicators within and between centers and between the peri-COVID-19 and control cohorts were tested using Cohen's <i>h</i> test to assess the standardized differences between the two groups.</p><p><strong>Results: </strong>Among 925 patients, distinct effects of the early COVID-19 pandemic on oncology services were observed. AC experienced a 50% reduction in patient consultations (98 <i>v</i> 197) versus a 12.5% reduction at PM (294 <i>v</i> 336). Similarly, AC experienced a higher proportion of stage IV disease presentations (42.9% <i>v</i> 29.9%; <i>P</i> = .015) and an increase in treatment delay (61.9% <i>v</i> 9.7%; <i>P</i> < .001) compared with prepandemic. At PM, a 10% increase in treatment interruption (32.4% <i>v</i> 22.3%; <i>P</i> < .001) and a higher rate of discontinuation of radiotherapy (9.4% <i>v</i> 1.1%; <i>P</i> < .001) were observed during the pandemic. Postsurgical readmission rates increased in both AC (20.9% <i>v</i> 2.6%; <i>P</i> < .001) and PM (10.5% <i>v</i> 3.6%; <i>P</i> < .01).</p><p><strong>Conclusion: </strong>The early phase of the COVID-19 pandemic affected the quality of care delivery for colorectal and anal cancers at both centers. However, the magnitude of this impact was greater in Brazil.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400037"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of First-Line Treatment With Anti-PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States.","authors":"Stephen V Liu, Anandaroop Dasgupta, Dominick Latremouille-Viau, Carmine Rossi, Pragya Rai, Fabrice Barlesi, Ticiana A Leal","doi":"10.1200/GO.24.00138","DOIUrl":"https://doi.org/10.1200/GO.24.00138","url":null,"abstract":"<p><strong>Purpose: </strong>Anti-PD-1/PD(L)1-based combination therapy is the standard of care in first line (1L) for metastatic nonsquamous non-small cell lung cancer (mnsqNSCLC) without driver alterations. This study aimed to evaluate real-world clinical outcomes in this population.</p><p><strong>Methods: </strong>Eligible physicians in the United States, Europe, and Japan abstracted information from medical charts of eligible adult patients with mnsqNSCLC (without <i>EGFR</i>/<i>ALK</i>, no known <i>ROS1</i> alterations) who initiated 1L anti-PD(L)1-based combination therapy for mnsqNSCLC between 2017 and 2021. Kaplan-Meier analyses were used to assess overall survival (OS), time-to-treatment discontinuation (TTD), and real-world progression-free survival (rwPFS) after 1L initiation.</p><p><strong>Results: </strong>Overall, 142 physicians contributed deidentified data from 430 patients' medical charts. The distribution of PD-L1 expression levels was 31.2% with tumor proportion score (TPS) <1%, 42.3% with TPS 1%-49%, and 26.5% with TPS ≥50%. In 1L, patients received anti-PD(L)1 + chemotherapy (84.6%), anti-PD(L)1 + anti-CTLA4 with or without chemotherapy (11.9%), and anti-PD(L)1 + chemotherapy + anti-vascular endothelial growth factor receptor (3.5%). The median OS was 21.7 months (TPS <1%: 18.3 months; TPS 1%-49%: 21.6 months; TPS ≥50%: 24.0 months). The median TTD was 11.0 months (TPS <1%: 9.1 months; TPS 1%-49%: 10.9 months; TPS ≥50%: 12.2 months). The median rwPFS was 11.2 months (TPS <1%: 9.3 months; TPS 1%-49%: 11.1 months; TPS ≥50%: 13.2 months).</p><p><strong>Conclusion: </strong>This study assessed the real-world clinical effectiveness of 1L anti-PD(L)1-based combination therapy for mnsqNSCLC. Results from this study were generally consistent with previous clinical trials and published real-world evidence in 1L mnsqNSCLC.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400138"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Patterns and Health Care Resource Utilization of Patients With Non-Small Cell Lung Cancer in Puerto Rico: The TREATLINES-ONCOLUNG Study.","authors":"Edgar I Miranda, Axel Gierbolini-Bermúdez, Rafael Quintana, Carlos R Torres-Cintrón, Karen J Ortiz-Ortiz","doi":"10.1200/GO.24.00089","DOIUrl":"10.1200/GO.24.00089","url":null,"abstract":"<p><strong>Purpose: </strong>Lung cancer remains one of the leading causes of cancer-related mortality worldwide. It is the third cause of death among patients with cancer in Puerto Rico (PR) and non-small cell lung cancer (NSCLC) is the most prevalent. This study aims to describe the first-line treatment (1LT) and health care resource utilization (HCRU) among patients with NSCLC in PR.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using the PR Central Cancer Registry Health Insurance Linkage Database to describe patients with NSCLC from 2012 to 2016. It describes sociodemographic and clinical characteristics on the basis of stage and histology and includes 1LT patterns and HCRU.</p><p><strong>Results: </strong>A total of 1,011 patients met the inclusion criteria. Most were male (57.1%), married (54.1%), and had no comorbidities (55.8%). A significant proportion of patients (71.1%) were diagnosed at stages III and IV, with nonsquamous cell carcinoma being the most prevalent histology group (75.9%). About 61.7% received systemic therapy, 36.7% received radiotherapy, and 21.9% underwent surgery. Platinum (Pt)-based combinations were the most common 1LT (82.9%). On average, patients had 4.7 emergency room visits, nearly six hospitalizations, and 22.4 outpatient visits annually. The mean frequencies of positron emission tomography, ultrasounds, computerized tomography scans, and magnetic resonance imaging were 0.95, 0.11, 4.88, and 0.91, respectively.</p><p><strong>Conclusion: </strong>To our knowledge, this study provides the first description of 1LT patterns, HCRU, and sociodemographic information among patients with NSCLC in PR. A significant number of patients were diagnosed at stage III or higher and received Pt-based systemic therapy as their 1LT. More research is required to investigate treatment patterns beyond the 1LT and to gain a comprehensive understanding of optimal care interventions and factors associated with early NSCLC diagnosis.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400089"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic Characteristics Influencing Overall Survival of Patients With Early- Versus Average-Onset Colorectal Cancer at a Tertiary Care Center in Indonesia.","authors":"Susanna Hilda Hutajulu, Daniel Howdon, Yasjudan Rastrama Putra, Susanti Susanti, Didik Setyo Heriyanto, Naomi Yoshuantari, Adeodatus Yuda Handaya, Bambang Purwanto Utomo, Sri Retna Dwidanarti, Johan Kurnianda, Aru Wisaksono Sudoyo, Mohammad Ilyas, Matthew John Allsop","doi":"10.1200/GO.24.00188","DOIUrl":"https://doi.org/10.1200/GO.24.00188","url":null,"abstract":"<p><strong>Purpose: </strong>There has been a global increase in early-onset colorectal cancer (EOCRC), yet there has been very limited exploration of its impact in Indonesia. This study aimed to determine the clinicopathologic characteristics and the overall survival (OS) of EOCRC compared with those of average-onset colorectal cancer (AOCRC).</p><p><strong>Methods: </strong>Medical records were retrospectively reviewed from all patients presenting with colorectal cancer (CRC) at Dr Sardjito General Hospital (Yogyakarta, Indonesia) between 2016 and 2019. Sociodemographic, clinicopathologic, and treatment variables were extracted. <i>t</i> Tests were used to compare characteristics of EOCRC and AOCRC patient groups. The Cox proportional hazards regression model was used to analyze age and other potential prognostic factors.</p><p><strong>Results: </strong>The total population (N = 1,276) comprised EOCRC (n = 149; 11.7%) and AOCRC (n = 1,127; 88.3%) patients. EOCRC patients were more likely to have a higher education level, be single, have out-of-pocket insurance, be underweight, and have signet ring histology (all <i>P</i> values <.05), compared with AOCRC patients. EOCRC and AOCRC groups had a comparable estimated 5-year OS of 34.2% and 36.9%, respectively. In multivariable analyses, performance status (Eastern Cooperative Oncology Group), hemoglobin level, cancer stage, and treatment intention were independent prognostic factors for OS (all <i>P</i> values <.05).</p><p><strong>Conclusion: </strong>To our knowledge, this first major study of EOCRC in Indonesia highlights its role in the overall burden of CRC and its connection with social determinants of health. Patients with EOCRC are more commonly underweight and generally have a higher proportion of signet ring histology than AOCRC, yet OS in both groups is similar. Future research is required to identify risk factors to inform the content and focus of public health education activities, alongside delineating the biology and causes of early and average onset of the disease.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400188"},"PeriodicalIF":3.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}